Grail teams with Quest on blood test for early cancer detection

By staff writers

February 23, 2021 -- Cancer diagnostics startup Grail has signed Quest Diagnostics to provide phlebotomy services for its upcoming Galleri multicancer early detection blood test.

Quest's phlebotomy network will provide blood specimen collection for Galleri once the test becomes available this year in the U.S. The company has approximately 2,200 patient service centers, as well as 5,000 mobile phlebotomists via its ExamOne business.

Grail said it plans to launch Galleri in the second quarter.

Copyright © 2021

To read this and get access to all of the exclusive content on, create a free account or sign in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?